Updated:
HanAll Biopharma
HanAll Biopharma develops biopharmaceuticals for autoimmune diseases and oncology using its technology platform. The company serves the pharmaceutical and...
HanAll Biopharma
HanAll Biopharma develops biopharmaceuticals for autoimmune diseases and oncology using its technology platform. The company serves the pharmaceutical and healthcare industries. Founded in 1973, HanAll Biopharma is based in Seoul, South Korea — formerly known as Seongyeong Pharmaceutical Co., Ltd.
General information
Firm type
Asset Manager
Location
Region
Asia
Country
South Korea
City
Hwaseong-si
Corporate office
Hwaseong-si, South Korea
Additional offices
San Francisco, United States · Seoul, South Korea
Principals
Christopher W Slavinsky
Chief Business Officer
Sector focus
Frequently asked questions
What is the commercial status of the HL161 licensing agreement?
HanAll disclosed receiving a termination notice for the HL161 licensing agreement in a regulatory filing. The company has not publicly detailed the financial impact or the counterparty involved. This leaves a gap in the known royalty revenue projections for that specific program.
How does HanAll Biopharma generate revenue?
Revenue comes primarily from licensing fees, milestone payments, and royalties on out-licensed drug candidates. The company does not sell therapies directly. Full-year 2025 revenue was 155 billion KRW, driven by double-digit growth in these partnered programs.
Which therapeutic areas does the pipeline target?
The disclosed pipeline targets autoimmune diseases and neurological disorders. Lead candidate batoclimab addresses a rare disease and has secured Orphan Drug Designation in Japan. The company is also collaborating on epigenetic reprogramming technology for aging-related conditions.
Who sets the firm's business development strategy?
Christopher W Slavinsky joined as Chief Business Officer in mid-2024 to lead commercial strategy and partnership development. His appointment followed a succession of licensing moves, indicating a centralized business-development function driving the firm's deal flow.
Where does HanAll Biopharma conduct operations?
The firm is headquartered in Hwaseong-si, South Korea, with an additional office in Seoul. San Francisco serves as its US base, positioning the team to access North American biotech partners and investors.
Profile maintained by Altss using OSINT (open-source intelligence), regulatory filings, licensed data partners, and verified direct submissions. Read the methodology. Last updated: . Continuous refresh with full update cycles at least every 30 days.
Need institutional-grade insight on asset managers?
Altss delivers:
Prefer a guided tour?
We’ll walk you through: